Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Finasteride · 1 trial · 2 indications
The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.
| Arm | Type | Description |
|---|---|---|
| Tadalafil | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tadalafil | DRUG | 5 milligrams (mg) administered orally, once daily for 26 weeks |
| Placebo | DRUG | Administered orally, once daily for 26 weeks |
| Finasteride | DRUG | 5mg administered orally, once daily for 26 weeks |
Inclusion Criteria: * Have not taken the following treatments within the indicated duration and agree not to use at any time during the study: * All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication. * Over...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | - | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | N/A | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | N/A | Undisclosed |
| Profound Medical Corp | PROF | 1 | - | Undisclosed |
Finasteride is used for benign prostatic hyperplasia (BPH), also called enlarged prostate, in men. It is a small molecule being studied in Phase 3 clinical development by Eli Lilly and Company. The drug is intended to treat urinary symptoms associated with an enlarged prostate.
Finasteride is a small molecule that targets the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT). By inhibiting this enzyme, Finasteride reduces DHT levels, which can help shrink the prostate and relieve symptoms of benign prostatic hyperplasia.
Finasteride is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 3 clinical development for benign prostatic hyperplasia.
Finasteride is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 3 trial has been completed, with no active trials currently ongoing.
Finasteride has one completed Phase 3 clinical trial, NCT01139762, titled "A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms." The trial enrolled 696 men aged 45 years and older with benign prostatic hyperplasia and was conducted in multiple countries including the United States, Argentina, Belgium, Brazil, and Canada.
Finasteride is the generic name for the drug also known as Proscar. In the context of this clinical development program, Finasteride is being studied in combination with tadalafil for the treatment of benign prostatic hyperplasia.